Mark Karwal

4.2k total citations
26 papers, 330 citations indexed

About

Mark Karwal is a scholar working on Oncology, Hepatology and Epidemiology. According to data from OpenAlex, Mark Karwal has authored 26 papers receiving a total of 330 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Hepatology and 9 papers in Epidemiology. Recurrent topics in Mark Karwal's work include Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Liver physiology and pathology (5 papers) and Liver Disease Diagnosis and Treatment (5 papers). Mark Karwal is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Liver physiology and pathology (5 papers) and Liver Disease Diagnosis and Treatment (5 papers). Mark Karwal collaborates with scholars based in United States, Germany and France. Mark Karwal's co-authors include M.A. Nathan, Seán Murphy, Richard S. Finn, Melanie B. Thomas, Fuad Ismail, Jean‐Luc Raoul, Joong‐Won Park, Christine Baudelet, Ian Walters and Hakim Bouterfa and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Mark Karwal

26 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Karwal United States 9 147 123 114 82 61 26 330
Seonggyu Byeon South Korea 11 283 1.9× 68 0.6× 46 0.4× 128 1.6× 79 1.3× 30 442
M. Kulke United States 8 182 1.2× 53 0.4× 126 1.1× 28 0.3× 116 1.9× 13 350
Ryu Otao Japan 10 122 0.8× 236 1.9× 150 1.3× 22 0.3× 45 0.7× 16 378
Melissa Frizziero United Kingdom 14 430 2.9× 68 0.6× 317 2.8× 35 0.4× 100 1.6× 45 636
Maria Luigia Vigliotti Italy 10 47 0.3× 75 0.6× 65 0.6× 89 1.1× 49 0.8× 17 309
Zhong-Guo Zhou China 11 196 1.3× 147 1.2× 75 0.7× 28 0.3× 62 1.0× 17 387
Matthew Lumley United Kingdom 7 94 0.6× 52 0.4× 54 0.5× 50 0.6× 31 0.5× 9 304
Vincent Hautefeuille France 13 364 2.5× 45 0.4× 182 1.6× 60 0.7× 33 0.5× 58 508
W Schmiegel Germany 11 118 0.8× 14 0.1× 45 0.4× 54 0.7× 59 1.0× 25 294
Osamu Matsui Japan 6 72 0.5× 357 2.9× 206 1.8× 24 0.3× 32 0.5× 8 460

Countries citing papers authored by Mark Karwal

Since Specialization
Citations

This map shows the geographic impact of Mark Karwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Karwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Karwal more than expected).

Fields of papers citing papers by Mark Karwal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Karwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Karwal. The network helps show where Mark Karwal may publish in the future.

Co-authorship network of co-authors of Mark Karwal

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Karwal. A scholar is included among the top collaborators of Mark Karwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Karwal. Mark Karwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Finn, Richard S., Masatoshi Kudo, Ivan Borbath, et al.. (2024). Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.. Journal of Clinical Oncology. 42(16_suppl). 4100–4100. 2 indexed citations
2.
Patel, Nikunj, Chad Gwaltney, Afsaneh Barzi, et al.. (2021). Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study. Quality of Life Research. 31(2). 473–485. 15 indexed citations
3.
Laethem, J-L. van, Ivan Borbath, Mark Karwal, et al.. (2021). 933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study. Annals of Oncology. 32. S819–S819. 1 indexed citations
4.
Spanheimer, Philip M., Anna C. Beck, Junlin Liao, et al.. (2021). A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer. American Journal of Clinical Oncology. 44(9). 456–462. 4 indexed citations
5.
Laethem, Jean‐Luc Van, Ivan Borbath, Mark Karwal, et al.. (2021). Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.. Journal of Clinical Oncology. 39(3_suppl). 297–297. 6 indexed citations
6.
Tanaka, Tomohiro, et al.. (2020). Performing thermal ablations for hepatomas – is it a worthy skill for hepatologists?. Annals of Hepatology. 19(5). 570–572. 1 indexed citations
7.
Galle, Peter R., Masatoshi Kudo, Josep M. Llovet, et al.. (2020). Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2. Journal of Hepatology. 73. S386–S387. 1 indexed citations
8.
Edeline, Julien, Mark Karwal, Andrew X. Zhu, et al.. (2020). RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).. Journal of Clinical Oncology. 38(4_suppl). 528–528. 2 indexed citations
9.
10.
11.
Park, Joong‐Won, Richard S. Finn, Mark Karwal, et al.. (2011). Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 17(7). 1973–1983. 110 indexed citations
12.
13.
Hortobágyi, Gabriel N., Robyn R. Young, Mark Karwal, et al.. (2010). A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice‐daily regimen to treat patients with recurrent metastatic breast cancer. Cancer. 116(10). 2301–2306. 7 indexed citations
14.
Karwal, Mark, et al.. (2009). Hemolysis and Elevated Transaminases Imitating Severe Preeclampsia. Obstetrics and Gynecology. 113(2). 545–547. 4 indexed citations
15.
Bushnell, David, Yusuf Menda, Thomas M. O’Dorisio, et al.. (2004). Effects of Intravenous Amino Acid Administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher™]) Treatment. Cancer Biotherapy and Radiopharmaceuticals. 19(1). 35–41. 15 indexed citations
16.
Kernstine, Kemp H., et al.. (2004). Tracheobronchial amyloidosis: A surgical disease with long-term consequences. Journal of Thoracic and Cardiovascular Surgery. 128(5). 789–792. 17 indexed citations
17.
Bushnell, David, Yusuf Menda, Mark T. Madsen, et al.. (2003). Assessment of Hepatic Toxicity from Treatment with 90 Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases. Cancer Biotherapy and Radiopharmaceuticals. 18(4). 581–588. 10 indexed citations
18.
Bushnell, David, Thomas M. O’Dorisio, Yusuf Menda, et al.. (2003). Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.. PubMed. 44(10). 1556–60. 53 indexed citations
19.
Karwal, Mark, et al.. (1998). Outcome of Transfusion of K:11 Erythrocytes in a Patient with Anti-K11 Antibody. Vox Sanguinis. 74(3). 205–208. 4 indexed citations
20.
Dreicer, Robert, et al.. (1997). The Role of Radionuclide Angiocardiography in the Treatment of Patients Receiving Doxorubicin-Based Chemotherapy. American Journal of Clinical Oncology. 20(2). 132–137. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seonggyu Byeon Breakdown of academic impact, for papers by M. Kulke Breakdown of academic impact, for papers by Ryu Otao Breakdown of academic impact, for papers by Melissa Frizziero Breakdown of academic impact, for papers by Maria Luigia Vigliotti Breakdown of academic impact, for papers by Zhong-Guo Zhou Breakdown of academic impact, for papers by Matthew Lumley Breakdown of academic impact, for papers by Vincent Hautefeuille Breakdown of academic impact, for papers by W Schmiegel Breakdown of academic impact, for papers by Osamu Matsui
Rankless by CCL
2026